ICP-189 is under clinical development by InnoCare Pharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ICP-189’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ICP-189 is under development for the treatment of solid tumors. It is administered through oral route. It acts by targeting tyrosine protein phosphatase non receptor type 11.
InnoCare Pharma overview
InnoCare Pharma (InnoCare) is a biopharmaceutical company that discovers and develops novel treatments for cancer and autoimmune diseases. The company’s pipeline product portfolio includes ICP-022 a Bruton Tyrosine Kinase (BTK) inhibitor to treat B cell malignancies; ICP-105, an inhibitor for the treatment of hepatocellular carcinoma (HCC); ICP-192 a novel compound that targets gene abnormalities in solid tumor. It serves in the therapeutic areas of gastrointestinal cancer, liver cancer, lupus and rheumatoid arthritis. The company builds a fully integrated biopharmaceutical platform with strong in-house research and development capabilities, including drug target identification and verification, preclinical evaluation, clinical trial design and execution, drug manufacturing and quality control. It has operational presence in the US and China. InnoCare is headquartered in Changping, Beijing, China.
For a complete picture of ICP-189’s drug-specific PTSR and LoA scores, buy the report here.